The Brain’s Redox Crisis: NAD, Mitochondria, and the Next Wave of Neuropsychiatric Treatment

What if some of the hardest brain disorders aren’t just “neurotransmitter problems” or “protein problems,” but redox problems — where the NAD⁺/NADH balance drifts, mitochondrial performance declines, oxidative stress rises, and inflammation becomes self-reinforcing? In this Deep Dive, Dr. Mike breaks down a review arguing that bioenergetic failure may be a shared organizing principle across neurodegenerative disease (Alzheimer’s, Parkinson’s, ALS) andpsychiatric illness (schizophrenia, bipolar disorder). We cover why raising NAD in blood isn’t the same as fixing compartmentalized brain redox, why clinical results have been mixed, and why the future of “redox therapy” hinges on biomarker-guided, mechanism-driven trials — not hype.

(Educational content only, not medical advice.)

-

Article Discussed in Episode:

Redox therapy for neuropsychiatric disorders: Molecular mechanisms and biomarker development

-

Key Quotes From Dr. Mike:

“The redox system is not peripheral to brain function. It is central to it.”

“We still do not fully understand NAD subcellular cycling.”

“We lack robust in vivo biomarkers that can really tell us whether a redox-based therapy is engaging its intended target in the brain.”

“Raising a precursor in blood is not the same as fixing a dynamic, compartmentalized, disease-specific, energetic failure inside the brain.”

“Ketogenic interventions do not just supply alternative fuel. They also appear to influence the NAD plus to NADH ratio.”

-

Key Points

• Redox ≠ generic antioxidants: the paper centers on the NAD⁺/NADH ratio as a core metabolic control variable.

• Shared energetic bottleneck: different diagnoses may share overlapping mitochondrial dysfunction + oxidative stress + inflammation.

• Why outcomes are mixed: the field still lacks clarity on subcellular NAD cycling (cytosol vs mitochondria vs nucleus).

• Biomarkers are the bottleneck: without in vivo target engagement measures in the brain, trials are hard to interpret.

• Therapy categories discussed: NAD-targeted strategies and ketogenic therapy as redox-modulating interventions.

• Ketogenic angle: not just alternate fuel — potentially shifts redox state and metabolic flexibility.

• Precision matters: heterogeneity across patients/stages means treatment should follow mechanism, not label.

-

Episode timeline

• 0:34 — Paper framing: brain energy, mitochondria, oxidative stress, treatment future

• 2:22 — Core concept: redox as NAD⁺/NADH ratio (not vague antioxidant talk)

• 3:44 — Neurodegeneration: Alzheimer’s, Parkinson’s, ALS through an energetic lens

• 5:09 — Psychiatry: schizophrenia/bipolar as potential bioenergetic + redox disorders

• 6:11 — Why NAD is central: respiration, stress signaling, survival programs

• 7:12 — Reality check: promising preclinical data, mixed clinical outcomes

• 7:35 — Key limitation: compartmentalized NAD pools + unclear subcellular cycling

• 8:22 — The measurement problem: lack of robust in vivo brain redox biomarkers

• 9:35 — Strategy 1: NAD-targeted supplementation (promise vs translation gap)

• 10:41 — Strategy 2: ketogenic therapy as a redox-shifting metabolic intervention

• 11:47 — The unifying loop: redox imbalance → mitochondrial dysfunction → ROS → inflammation → worse mitochondria

• 13:24 — Why neuroimaging/biomarkers are essential for precision redox therapy

• 14:48 — Cross-diagnostic mechanism: treatment may follow mechanism, not diagnoses

• 15:50 — What’s needed next: mechanism-first trials + target engagement + better biomarkers

• 16:34 — Final synthesis + takeaway

-

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com

-

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

BioLight:

Website

Instagram

YouTube

Facebook